IP Library › Granted Patent US 12,421,323
Granted Patent B2
US 12,421,323 · App. 18/316,804 · Granted Sep 23, 2025

Multispecific antibody molecules comprising lambda and kappa light chains

Inventors: Andreas Loew (Boston, MA); Brian Edward Vash (Cambridge, MA); Stephanie J. Maiocco (Arlington, MA)
Assignee: MARENGO THERAPEUTICS, INC.
C07K16/468A61P35/00C07K16/00C07K16/246C07K16/2818C07K16/2878C07K16/40C07K16/44C07K2317/31C07K2317/515C07K2317/567
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,421,323
App. No.
18/316,804
Granted
Sep 23, 2025
Kind
B2
Abstract

Multispecific, e.g., bispecific, antibody molecules that include a kappa light chain polypeptide and one lambda light chain polypeptide, and methods of making and using the multispecific antibody molecules, are disclosed.

Claims (42)

1. An antibody molecule comprising four non-contiguous polypeptides, wherein:

(a) a first heavy chain polypeptide (HCP1) comprising a sequence having at least 95% sequence identity to the sequence of amino acids 120-449 of SEQ ID NO: 164;

(b) a kappa light chain polypeptide (KLCP) comprising a sequence having at least 95% sequence identity to the sequence of amino acids 111-213 of SEQ ID NO: 165;

(c) a second heavy chain polypeptide (HCP2) comprising a sequence having at least 95% sequence identity to the sequence of amino acids 121-450 of SEQ ID NO: 166; and

(d) a lambda light chain polypeptide (LLCP) comprising a sequence having at least 95% sequence identity to the sequence of amino acids 111-216 of SEQ ID NO: 167;

wherein the HCP1 and the HCP2 are a knob and hole pair; and wherein:

(A) (i) the KLCP binds to the HCP1 with a higher affinity than the affinity of the LLCP to the HCP1 and the affinity of the KLCP to the HCP2; and

(ii) the LLCP binds to the HCP2 with a higher affinity than the affinity of the KLCP to the HCP2 and the affinity of the LLCP to the HCP1; or

(B) (i) the LLCP binds to the HCP1 with a higher affinity than the affinity of the KLCP to the HCP1 and the affinity of the LLCP to the HCP2; and

(ii) the KLCP binds to the HCP2 with a higher affinity than the affinity of the LLCP to the HCP2 and the affinity of the KLCP to the HCP1.

2. The antibody molecule of claim 1 , wherein the HCP2 further comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 403.

3. The antibody molecule of claim 1 , wherein the LLCP comprises a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 404.

4. The antibody molecule of claim 1 , wherein the HCP1 comprises a sequence identical to the sequence of amino acids 120-217 of SEQ ID NO: 164 or the HCP2 comprises a sequence identical to the sequence of amino acids 121-218 of SEQ ID NO: 166.

5. The antibody molecule of claim 1 , wherein the HCP1 comprises a sequence identical to the sequence of amino acids 351-409 of SEQ ID NO: 164, and the HCP2 comprises a sequence identical to the sequence of amino acids 352-410 of SEQ ID NO: 166.

6. The antibody molecule of claim 1 , wherein the HCP1 comprises the sequence of amino acids 120-449 of SEQ ID NO: 164.

7. The antibody molecule of claim 1 , wherein the HCP2 comprises the sequence of amino acids 121-450 of SEQ ID NO: 166.

8. The antibody molecule of claim 1 , wherein the LLCP comprises the sequence of amino acids 111-216 of SEQ ID NO: 167.

9. The antibody molecule of claim 1 , wherein the KLCP comprises the sequence of amino acids 111-213 of SEQ ID NO: 165.

10. The antibody of claim 1 , wherein:

(i) the HCP1 comprises the sequence of amino acids 120-449 of SEQ ID NO: 164;

(ii) the HCP2 comprises the sequence of amino acids 121-450 of SEQ ID NO: 166;

(iii) the LLCP comprises the sequence of amino acids 111-216 of SEQ ID NO: 167; and

(iv) the KLCP comprises the sequence of amino acids 111-213 of SEQ ID NO: 165.

11. The antibody molecule of claim 1 , wherein:

(A) the HCP1 does not bind to the LLCP and the HCP2 does not bind to the KLCP, or

(B) the HCP1 does not bind to the KLCP and the HCP2 does not bind to the LLCP.

12. The antibody molecule of claim 1 , wherein:

(a) the HCP1 comprises a first heavy chain constant region sequence (first HCCRS),

(b) the KLCP comprises a kappa light chain constant region sequence (KLCCRS),

(c) the HCP2 comprises a second heavy chain constant region sequence (second HCCRS), and

(d) the LLCP comprises a lambda light chain constant region sequence (LLCCRS); and

wherein:

(i) the first HCCRS does not comprise a mutation that promotes the preferential pairing of the HCP1 and the KLCP, and the KLCCRS does not comprise a mutation that promotes the preferential pairing of the KLCP and the HCP1; and

(ii) the second HCCRS does not comprise a mutation that increases the affinity of the HCP2 to the LLCP, and the LLCCRS does not comprise a mutation that promotes the preferential pairing of the LLCP and the HCP2.

13. The antibody molecule of claim 1 , wherein:

(a) the HCP1 comprises a first heavy chain constant region sequence (first HCCRS),

(b) the KLCP comprises a kappa light chain constant region sequence (KLCCRS),

(c) the HCP2 comprises a second heavy chain constant region sequence (second HCCRS), and

(d) the LLCP comprises a lambda light chain constant region sequence (LLCCRS); and

wherein:

(i) the first HCCRS does not comprise a mutation that increases the affinity of the HCP1 to the LLCP, and the LLCCRS does not comprise a mutation that promotes the preferential pairing of the LLCP and the HCP1; and

(ii) the second HCCRS does not comprise a mutation that increases the affinity of the HCP2 to the KLCP, and the KLCCRS does not comprise a mutation that promotes the preferential pairing of the KLCP and the HCP2.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2024
From: LOEW, ANDREAS; VASH, BRIAN EDWARD; MAIOCCO, STEPHANIE J.
To: ELSTAR THERAPEUTICS, INC.
Reel/Frame 068010/0616 →
CHANGE OF NAME Recorded Jul 17, 2024
From: ELSTAR THERAPEUTICS, INC.
To: MARENGO THERAPEUTICS, INC.
Reel/Frame 068420/0038 →
Continuity (4)
Division 16335822
Provisional Application 62399319 · Sep 23, 2016
Provisional Application 62474569 · Mar 21, 2017
Related Publication 20230272119A1 · Aug 31, 2023
References Cited (173)
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 5223409A · Ladner et al. · 1993 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5624821A · Winter et al. · 1997 [cited by applicant]
US 5648260A · Winter et al. · 1997 [cited by applicant]
US 5693761A · Queen et al. · 1997 [cited by applicant]
US 5693762A · Queen et al. · 1997 [cited by applicant]
US 5731116A · Matsuo et al. · 1998 [cited by applicant]
US 5811097A · Allison et al. · 1998 [cited by applicant]
US 5849500A · Breitling et al. · 1998 [cited by applicant]
US 7476724B2 · Dennis et al. · 2009 [cited by applicant]
US 7501121B2 · Tchistiakova et al. · 2009 [cited by applicant]
US 7943743B2 · Korman et al. · 2011 [cited by applicant]
US 7943873B2 · Gopikrishnan et al. · 2011 [cited by applicant]
US 8008449B2 · Korman et al. · 2011 [cited by applicant]
US 8354509B2 · Carven et al. · 2013 [cited by applicant]
US 8552156B2 · Takayanagi et al. · 2013 [cited by applicant]
US 8609089B2 · Langermann et al. · 2013 [cited by applicant]
US 11291721B2 · Loew · 2022 [cited by examiner]
US 11673971B2 · Loew · 2023 [cited by examiner]
US 20040009530A1 · Wilson et al. · 2004 [cited by applicant]
US 20100028330A1 · Collins et al. · 2010 [cited by applicant]
US 20110150892A1 · Thudium et al. · 2011 [cited by applicant]
US 20120039906A1 · Olive · 2012 [cited by applicant]
US 20120114649A1 · Langermann et al. · 2012 [cited by applicant]
US 20130317200A1 · Elson et al. · 2013 [cited by applicant]
US 20140044728A1 · Takayanagi et al. · 2014 [cited by applicant]
US 20190338048A1 · Urosev et al. · 2019 [cited by applicant]
CN 102858800A · 2013 [cited by applicant]
CN 103261220A · 2013 [cited by applicant]
CN 104011221A · 2014 [cited by applicant]
CN 105612182A · 2016 [cited by applicant]
EP 0125023A1 · 1984 [cited by applicant]
EP 0171496A2 · 1986 [cited by applicant]
EP 0173494A2 · 1986 [cited by applicant]
EP 0184187A2 · 1986 [cited by applicant]
EP 0388151A1 · 1990 [cited by applicant]
EP 0519596A1 · 1992 [cited by applicant]
EP 2581113A1 · 2013 [cited by applicant]
GB 2188638A · 1987 [cited by applicant]
JP 2013545738A · 2013 [cited by applicant]
JP 2015502409A · 2015 [cited by applicant]
WO WO8601533A1 · 1986 [cited by applicant]
WO WO8605133A1 · 1986 [cited by applicant]
WO WO8702671A1 · 1987 [cited by applicant]
WO WO9002809A1 · 1990 [cited by applicant]
WO WO9100906A1 · 1991 [cited by applicant]
WO WO9110741A1 · 1991 [cited by applicant]
WO WO9117271A1 · 1991 [cited by applicant]
WO WO9201047A1 · 1992 [cited by applicant]
WO WO9203917A1 · 1992 [cited by applicant]
WO WO9203918A1 · 1992 [cited by applicant]
WO WO9209690A2 · 1992 [cited by applicant]
WO WO9215679A1 · 1992 [cited by applicant]
WO WO9218619A1 · 1992 [cited by applicant]
WO WO9220791A1 · 1992 [cited by applicant]
WO WO9301288A1 · 1993 [cited by applicant]
WO WO9404678A1 · 1994 [cited by applicant]
WO WO9856915A2 · 1998 [cited by applicant]
WO WO9945110A1 · 1999 [cited by applicant]
WO WO0034784A1 · 2000 [cited by applicant]
WO WO0056772A1 · 2000 [cited by applicant]
WO WO0060070A1 · 2000 [cited by applicant]
WO WO0164942A1 · 2001 [cited by applicant]
WO WO03074679A2 · 2003 [cited by examiner]
WO WO2006105338A2 · 2006 [cited by applicant]
WO WO2006121168A1 · 2006 [cited by applicant]
WO WO2007005874A2 · 2007 [cited by applicant]
WO WO2009101611A1 · 2009 [cited by applicant]
WO WO2009114335A2 · 2009 [cited by applicant]
WO WO2010019570A2 · 2010 [cited by applicant]
WO WO2010027827A2 · 2010 [cited by applicant]
WO WO2010077634A1 · 2010 [cited by applicant]
WO WO2011066342A2 · 2011 [cited by applicant]
WO WO2011080350A1 · 2011 [cited by applicant]
WO WO2011155607A1 · 2011 [cited by applicant]
WO WO2012023053A2 · 2012 [cited by applicant]
WO WO2013079174A1 · 2013 [cited by applicant]
WO WO2013096291A2 · 2013 [cited by applicant]
WO WO2014008218A1 · 2014 [cited by applicant]
WO WO2015052230A1 · 2015 [cited by applicant]
WO WO2017059551A1 · 2017 [cited by applicant]
WO WO2018057955A1 · 2018 [cited by applicant]
Lund et al., The Journal of Immunology 157:4963-4969 (Year: 1996). [cited by examiner]
Piche-Nicholas et al., MABS 10(1): 81-94 (Year: 2018). [cited by examiner]
Adachi, Osamu et al. Targeted Disruption of the MyD88 Gene Results in Loss of IL-1-and IL-8-Mediated Function. Immunity 9(1):143-150 (1998). [cited by applicant]
Co-pending U.S. Appl. No. 18/301,052, inventors Loew; Andreas et al., filed Apr. 13, 2023. [cited by applicant]
Dixon, Andrew S. et al. NanoLuc complementation reporter optimized for accurate measurement of protein interactions in cells. ACS Chemical Biology 11(2):400-408 (2015). [cited by applicant]
Dorfman, Albert, and Melvin L Ott. A turbidimetric method for the assay of hyaluronidase. The Journal of biological chemistry 172(2):367-375 (1948). [cited by applicant]
Doyle, Sean et al. IRF3 Mediates a TLR3/TLR4-Specific Antiviral Gene Program. Immunity 17(3):251-263 (2002). [cited by applicant]
Ipilimumab. CAS 477202-00-9. chemicalbook.com [Website] Retrieved Oct. 8, 2024 at: https://www.chemicalbook.com/CASEN_477202-00-9.htm. 3 pages. [cited by applicant]
Kabat, Elvin A. et al. Sequences of Proteins of Immunological Interest. Fifth Edition, NIH Pub. No. 91-3242. Public Health Service, U.S. Department of Health and Human Services, National Institutes of Health: 647-669 (1… [cited by applicant]
Seidel, Ursula J E. et al. Natural Killer Cell Mediated Antibody-dependent Cellular Cytotoxicity in Tumor Immunotherapy With Therapeutic Antibodies. Frontiers in Immunology 4:76, 1-8 (2013). [cited by applicant]
U.S. Appl. No. 16/335,822 Notice of Allowance dated Jan. 10, 2023. [cited by applicant]
Mar. 24, 2022 Final Office Action U.S. Appl. No. 16/335,822. [cited by applicant]
Aug. 10, 2021 Non-Final Office Action U.S. Appl. No. 16/335,822. [cited by applicant]
Agostinis, P. et al, “Photodynamic Therapy of Cancer: An Update”, CA Cancer J. Clin, 2011, vol. 61, No. 4, pp. 250-281. [cited by applicant]
Al-Lazikani, B. et al, “Standard Conformations for Canonical Structures of Immunoglobulins”, J. Mol. Biol., 1997, vol. 273 , pp. 927-948. [cited by applicant]
Altschul et al., Gapped Blast and Psi-Blast: A New Generation Of Protein Database Search Programs. Nucleic Acids Research 25(17):3389-3402 (1997). [cited by applicant]
Altschul, S F, et al., Basic Local Alignment Search Tool. Journal of Molecular Biology 215(3):403-410 (1990). [cited by applicant]
Arnon, T.I. et al, “Recognition of viral hemagglutinins by NKp44 but not by NKp30”, Eur J. Immunol., 2001, vol. 31, No. 9, pp. 2680-2689. [cited by applicant]
Barbas, C.F. et al, “Assembly of combinatorial antibody libraries on phage surfaces: The gene III site”, PNAS, 1991, vol. 88, pp. 7978-7982. [cited by applicant]
Barrios, Y. et al, “Length of antibody heavy chain complementarity determining region 3 as a specificity-determining factor”, Journal of Molecular Recognition, 2004, vol. 17, pp. 332-338. [cited by applicant]
Beidler,C.B. et al., “Cloning and high level expression of a chimeric antibody with specificity for human carcinoembryonic antigen”, J. Immuno, 1988, vol. 141, pp. 4053-4060. [cited by applicant]
Better, M. et al., “ [cited by applicant]
Bird et al., Single-Chain Antigen-binding Proteins. Science 242(4877):423-426 (1988). [cited by applicant]
Bruggemann, M. et al., Designer Mice: The Production of Human Antibody Repertories in Transgenic Animals, Terhorst C. Malavasi F, Albertini A (eds): Generation of Antibodies by Cell and Gene Immortalization, Year Immuno… [cited by applicant]
Bruggemann, M. et al., “Human antibody production in transgenic mice: expression from 100kb of the human IgH locus”, Eur J. Immunol, 1991, vol. 21, pp. 1323-1326. [cited by applicant]
Chothia, C. et al., “Canonical Structures for the Hypervariable Regions of Immunoglobulins”, J. Mol. Biol, 1987, vol. 196, pp. 901-917. [cited by applicant]
Clackson, T. et al., Making antibody fragments using phage display libraries, Nature, 1991, vol. 352, pp. 624-628. [cited by applicant]
Colcher, D. et al, “Single-Chain Antibodies in Pancreatic Cancer”, Ann Ny Acad Sci, 1999, vol. 880, pp. 263-280. [cited by applicant]
Coloma, J. et al, “Design and production of novel tetravalent bispecific antibodies”, Nature Biotech, 1997, vol. 15, pp. 159-163. [cited by applicant]
Costa-Mattioli, M. et al., “RAPping production of type I interferon in pDCs through mTOR”, 2008, Nature Immunol, vol. 9, No. 10, pp. 1097-1099. [cited by applicant]
Dhimolea et al., “World Bispecific Antibody Summit, Sep. 27-28, 2011, Boston, MA”, mAbs, 2012, vol. 4, Issue 1, pp. 4-13. [cited by applicant]
Edwards, B.M. et al., “The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS”, J. Mol. Biol., 2003, vol. 334, pp. 103-118. [cited by applicant]
Fischer, N. et al., “Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG”, Nature Communications, 2015, 6:6113, pp. 1-12. [cited by applicant]
Fuchs, P. et al., “Targeting Recombinant Antibodies to the surface of [cited by applicant]
Garrard, L. et al., “FAB Assembly and Enrichment in a Monovalent Phage Display System”, Nature Publishing Group, 1991, vol. 9, pp. 1373-1377. [cited by applicant]
Garrity, D. et al, “The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure”, Proc Natl Acad Sci USA, 2005, vol. 102, No. 21, pp. 7641-7646. [cited by applicant]
Gram, H. et al, In vitro selection and affinity maturation of antibodies from a naïve combinatorial immunoglobulin library, PNAS, 1992, vol. 89, pp. 3576-3580. [cited by applicant]
Green, L.L. et al, “Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACS”, Nature Genet, 1994, vol. 7, pp. 13-21. [cited by applicant]
Griffiths, A.D. et al, “Human anti-self antibodies with high specificity from phage display libraries”, The EMBO Journal, 1993, vol. 12, No. 2, pp. 725-734. [cited by applicant]
Hamid, O. et al., “Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma”, The New England Journal of Medicine, 2013, vol. 369, No. 2, pp. 134-144. [cited by applicant]
Hawkins, R. et al., “Selection of phage antibodies by binding affinity. Mimicking affinity maturation”, J. Mol. Biol., 1992, vol. 226, No. 3, pp. 889-896. [cited by applicant]
Hay, B. et al., “Bacteriophage cloning and [cited by applicant]
Hoogenboom, H.R. et al, “Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains”, Nuc Acid Res, 1991, vol. 19, No. 15, pp. 4133-4137. [cited by applicant]
Huse, W. et al., “Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda” Science, 1989, vol. 246, No. 4935, pp. 1275-1281. [cited by applicant]
Huston et al., Protein Engineering Of Antibody Binding Sites: Recovery Of Specific Activity In An Anti-digoxin Single-chain Fv Analogue Produced In [cited by applicant]
International Search Report and Written Opinion issued in PCT/US2017/053053, mailed Feb. 27, 2018. [cited by applicant]
Jayaram et al., “Germline VH/VL pairing in antibodies”, Protein Engineering, Design & Selection, 2012, vol. 25, No. 10, pp. 523-529. [cited by applicant]
Jones et al., Replacing The Complementarity-determining Regions In A Human Antibody With Those From A Mouse. Nature 321(6069):522-525 (1986). [cited by applicant]
Lefranc, M.P.., “IMGT, the international ImMunoGene Tics database”, Nucleic Acids Research, 2001, vol. 29, No. 1, pp. 207-209. [cited by applicant]
Li P. et al., “Design and synthesis of paclitaxel conjugated with an ErbB2-recognizing peptide,” EC-1, 2007, Biopolymers, vol. 87, No. 4, pp. 225-230. [cited by applicant]
Liu, A. et al., “Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity”, J Immunol, 1987, vol. 139, No. 10, pp. 3521-3526. [cited by applicant]
Liu, A.Y. et al., “Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells”, PNAS, 1987, vol. 84, pp. 3439-3443. [cited by applicant]
Liu, D.Z. et al, “Synthesis of 2′-paclitaxel 2-glucopyranosyl succinate for specific targeted delivery to cancer cells”, Bioorganic & Medicinal Chemistry Letters, 2007, vol. 17, pp. 617-620. [cited by applicant]
Lloyd et al., Modelling the Human Immune Response: Performance of a 10″ Human Antibody Repertoire Against a Broad Panel of Therapeutically Relevant Antigens. Protein Engineering Design & Selection. 22(3):159-168 (2009). [cited by applicant]
Lobuglio, A. et al., “Phase I Clinical Trial of CO17-1A Monoclonal Antibody”, Hybridomia, 1986, vol. 5, No. 1, pp. S117-S123. [cited by applicant]
Lonberg et al., Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368:856-859 (1994). [cited by applicant]
Maccallum, R M, et al., Antibody-Antigen Interactions: Contact Analysis And Binding Site Topography. Journal of Molecular Biology 262(5):732-745 (1996). [cited by applicant]
Malinge, presentation entitled “Maximizing Assembly and Yield of Unmodified Bispecific Antibodies,” World Bispecific Summit 2015, retrieved from the internet at bispecific.com/wp-content/uploads/sites/90/2015/07/Day-1-1… [cited by applicant]
Mandelboim, O. et al., “Recognition of hemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells”, Nature, 2001, vol. 409, No. 6823, pp. 1055-1060. [cited by applicant]
Martin, A. et al., “Chapter 3: Protein Sequence and Structure Analysis of Antibody Variable Domains”, In: Antibody Engineering Lab Manual (Ed: Duebel, S. and Kontermann, R., Springer-Verlag, Heidelberg), 2010, vol. 2, p… [cited by applicant]
Martin, F. et al., “The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6”, EMBO J., 1994, vol. 13, No. 22, pp. 5303-5309. [cited by applicant]
Mcconnell, S.J. et al., “Tendamistat as a scaffold for conformationally constrained phage peptide libraries”, J Mol Biol, 1995, vol. 250, No. 4, pp. 460-470. [cited by applicant]
Meyers, E. et al., “Optimal alignments in linear space”, Cabios, 1988, vol. 4, No. 1, pp. 11-17. [cited by applicant]
Morrison, Sherie L., “Transfectomas provide novel chimeric antibodies”, Science, 1985, vol. 229, No. 4719, pp. 1202-1207. [cited by applicant]
Morrison, S.L. et al, “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains”, Proc Natl Acad Sci, 1984, vol. 81, pp. 6851-6855. [cited by applicant]
Needleman et al., A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins. Journal of Molecular Biology 48:444-453 (1970). [cited by applicant]
Nishimura, Y. et al., “Recombinant Human-Mouse Chimeric Monoclonal Antibody Specific for Common Acute Lymphocytic Leukemia Antigen”, Canc. Res, 1987, vol. 47, pp. 999-1005. [cited by applicant]
Oi, V. et al., “Chimeric Antibodies”, BioTechniques, 1986, vol. 4, No. 3, pp. 214-221. [cited by applicant]
Pardoll, D.M., “The blockade of immune checkpoints in cancer immunotherapy”, Nat Rev Cancer, 2012, Vo. 12, pp. 252-264. [cited by applicant]
Park, Y.P. et al., “Complex Regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the γc cytokines and TGF-β1”, Blood, 2011, vol. 118, No. 11, pp. 3019-3027. [cited by applicant]
Rakoff-Nahoum, S. et al., “Toll-like receptors and cancer”, Nat Revs Cancer, 2009, vol. 9, pp. 57-63. [cited by applicant]
Reiter, Y et al., “Antibody Engineering of Recombinant Fv Immunotoxins for Improved Targeting of Cancer: Disulfide-stabilized Fv Immunotoxins”, Clin Cancer Res, 1996, vol. 2, pp. 245-252. [cited by applicant]
Ridgway, J. et al, Knobs-into holes engineering of antibody CH3 domains for heavy chain heterodimerization, Protein Engineering, 1996, vol. 9, No. 7. pp. 617-621. [cited by applicant]
Rosenberg, S. et al., “Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma”, New Eng J of Med, 1988, vol. 319, pp. 1676-1680. [cited by applicant]
Rudikoff et al., Single Amino Acid Substitution Altering Antigen-binding Specificity. PNAS USA 79(6):1979-1983 (1982). [cited by applicant]
Saleh, M.N. et al, “A phase II trial of murine monoclonal antibody 17-1A and interferon-γ: clinical and immunological data”, Cancer Immunol Immunother, 1990, vol. 32, pp. 185-190. [cited by applicant]
Scaviner, D. et al., “Protein displays of the human immunoglobulin heavy, kappa and lambda variable and joining regions”, Exp. Clin. Immunogenet., 1999, vol. 16, pp. 234-240. [cited by applicant]
Shaw, D. et al., “Mouse/human chimeric antibodies to a tumor-associated antigen: biologic activity of the four human IgG subclasses”, Journal of the National Cancer Institute, 1988, vol. 80, No. 19. pp. 1553-1559. [cited by applicant]
Spiess, C. et al, “Alternative molecular formats and therapeutic applications for bispecific antibodies”, Molecular Immunology, 2015, vol. 67, pp. 95-106. [cited by applicant]
Sun, L.K. et al., “Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A”, PNAS, 1987, vol. 84, pp. 214-218. [cited by applicant]
Thorpe, P. E., “Vascular Targeting Agents as Cancer Therapeutics”, Clinc Cancer Res, 2004, vol. 10, pp. 415-427. [cited by applicant]
Toughiri et al., “Comparing domain interactions within antibody Fabs with kappa and lambda light chains,” mAbs, 2016, vol. 8, No. 7, pp. 1276-1285. [cited by applicant]
Tramontano et al.: The making of the minibody: an engineered beta-protein for the display of conformationally constrained peptides. J. Mol. Recognition. 7:9-24 (1994). [cited by applicant]
Tuaillon, N. et al., “Human immunoglobulin heavy-chain minilocus recombination in transgenic mice: Gene-segment use in μ and γ transcripts,” PNAS, 1993, vol. 90, pp. 3720-3724. [cited by applicant]
Verhoeyen, M. et al., “Reshaping Human Antibodies: Grafting an Antilysozyme Activity”, Science, 1988, vol. 239, pp. 1534-1536. [cited by applicant]
Weidle, U. et al, “The Intriguing Options of Multispecific Antibody Formats for Treatment of Cancer”, Cancer Genomics & Proteomics, 2013, vol. 1, pp. 1-18. [cited by applicant]
Wood, C. R. et al., “The synthesis and in vivo assembly of functional antibodies in yeast”, Nature Publishing Group, 1985, vol. 314, No. 4, pp. 446-449. [cited by applicant]
Wu et al., Humanization Of A Murine Monoclonal Antibody By Simultaneous Optimization Of Framework And CDR residues. J Mol Biol 294(1):151-162 (Nov. 19, 1999). [cited by applicant]
Xu, Y. et al., “Production of bispecific antibodies in “knobs-into-holes” using a cell-free expression system”, mAbs, 2015,. vol. 7. MP/ 1, pp. 231-242. [cited by applicant]